{
    "clinical_study": {
        "@rank": "139818", 
        "brief_summary": {
            "textblock": "Reduction in size and number of oral premalignant lesions"
        }, 
        "brief_title": "Chemoprevention of Oral Premalignant Lesions", 
        "completion_date": {
            "#text": "April 2004", 
            "@type": "Actual"
        }, 
        "condition": "Precancerous Conditions", 
        "condition_browse": {
            "mesh_term": "Precancerous Conditions"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  8mm oral premalignant lesion that has not been biopsied in the past 6 months\n\n        Exclusion Criteria:\n\n          -  Taking >100mg daily dose of NSAIDS (Non-steroidal anti-inflammatory drugs)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "42", 
        "firstreceived_date": "May 8, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00036283", 
            "org_study_id": "NQ4-00-02-011"
        }, 
        "intervention": {
            "intervention_name": "Celecoxib", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Celecoxib"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "September 25, 2008", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=NQ4-00-02-011&StudyName=Chemoprevention+of+Oral+Premalignant+Lesions"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Farmington", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06030-3805"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shreveport", 
                        "country": "United States", 
                        "state": "Louisiana", 
                        "zip": "71103"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ann Arbor", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48109"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Minneapolis", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55455"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98195-6607"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Clinical Protocol For A Phase II Double-Blind, Placebo-Controlled, Randomized Study Of Celecoxib (Sc-58635) In Oral Premalignant Lesions, Investigator IND", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_outcome": [
            {
                "measure": "To evaluate the efficacy of celecoxib in subjects with Early or Advanced oral premalignant lesion (OPL)"
            }, 
            {
                "measure": "by both clinical response (reduction in size of all lesions,"
            }, 
            {
                "measure": "prevention of growth in the index lesion and of any new lesions)"
            }, 
            {
                "measure": "and histological response (change in histological grade)."
            }, 
            {
                "measure": "To evaluate the safety of chronic multiple dosing of celecoxib in this patient population."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00036283"
        }, 
        "responsible_party": {
            "name_title": "Director, Clinical Trial Disclosure Group", 
            "organization": "Pfizer, Inc."
        }, 
        "secondary_outcome": {
            "measure": "To evaluate the treatment effects in modulating the expression of genomic and proliferative markers after 12 weeks of treatment with study drug, followed by 12 weeks off study drug."
        }, 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2000", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "September 2008"
    }, 
    "geocoordinates": {
        "Pfizer Investigational Site": "47.606 -122.332"
    }
}